SCHEMBL712975

SCHEMBL712975

O=[As](Oc1ccccc1)(Oc1ccccc1)Oc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.45
TSHR P16473 1/20 0.45
CA4 P22748 3/20 0.41
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
SRC P12931 1/20 0.39
KCNA3 P22001 1/20 0.38
CA6 P23280 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALOX15 P16050 1/20 0.37
CA5A P35218 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
MAOA P21397 2/20 0.35
NR1H2 P55055 1/20 0.35
BAX Q07812 1/20 0.35
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064518 0.78 CA4 (0.46) LTA4HTSHRCA4CA9CA1
SCHEMBL367452 0.78 CA4 (0.46) LTA4HTSHRCA4CA9CA1
SCHEMBL2001538 0.72 CA4 (0.41) LTA4HTSHRCA4CA9CA1
SCHEMBL15477270 0.72 CA4 (0.52) LTA4HTSHRCA4CA9CA1
SCHEMBL66653 0.65
SCHEMBL1057667 0.65
SCHEMBL3955287 0.65
SCHEMBL14905 0.63 LTA4H (0.60) LTA4HTSHRCA4CA9CA1
Diphenylether SCHEMBL9061108 0.63 LTA4H (1.00) LTA4HTSHRCA4CA9CA1
Diphenylether SCHEMBL2461810 0.63 LTA4H (1.00) LTA4HTSHRCA4CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661831-A Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2025-03-21 CN disclosed
CN-119317594-A Method for preparing hydrazine hydrate by utilizing absorption tower 阿科玛法国 2025-01-14 CN disclosed
CN-119317595-A Process for the preparation of azines using cascade reactors 阿科玛法国 2025-01-14 CN disclosed
CN-119137271-A Compositions and methods for capping RNA 维乎医疗有限公司 2024-12-13 CN disclosed
CN-115484932-B Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2024-12-10 CN disclosed
CN-118076360-A Compositions and methods for targeted RNA delivery 维乎医疗有限公司 2024-05-24 CN disclosed
EP-3221340-B1 DIAGNOSTIC METHOD EMPLOYING HUMAN NEUTROPHIL LIPOCALIN (HNL) P & M VENGE AB (SE) 2024-05-22 EP disclosed
CN-110702921-B Methods and compositions for diagnosing and prognosing kidney injury and renal failure 阿斯图特医药公司 2024-02-06 CN disclosed
CN-110291197-B Detection method 基因复制股份有限公司 2024-01-12 CN disclosed
EP-3858948-B1 QUANTUM DOT TCL TECH GROUP CORP (CN) 2023-11-22 EP disclosed
US-20020115566-A1 Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-08-22 US disclosed
US-20020026047-A1 Calixpyrroles, calixpyridinopyrroles, and calixpyridines BOARD OF REGENTS, THE 2002-02-28 US disclosed
US-6262257-B1 SELECTIVE ION- AND NEUTRAL MOLECULE-BINDING AGENTS FORMING SUPRAMOLECULAR ENSEMBLES, AND ION- AND NEUTRAL MOLECULE-SEPARATION AGENTS BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM 2001-07-17 US disclosed
US-6126743-A REACTING THREE DIFFERENT METAL OXIDES OR COMPOUNDS OF SPECIFIC DIAMETERS, FIRING OR HEATING THE MIXTURE AT A TEMPERATURE 400-1200 DEGREE C AT WHICH CRYSTAL PHASE CAN BE FORMED SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-10-03 US disclosed
EP-0891364-A1 CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1999-01-20 EP disclosed
WO-1997037995-A1 CALIXPYRROLES, CALIXPYRIDINOPYRROLES AND CALIXPYRIDINES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1997-10-16 WO disclosed
US-5422038-A Ferroelectric liquid crystal material with sufficient spontaneous polarization, high speed response capability, wide temperature range SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-06-06 US disclosed
EP-0416946-B1 Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same SUMITOMO CHEMICAL CO (JP) 1994-11-09 EP disclosed
EP-0416946-A2 Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1991-03-13 EP disclosed
US-4788346-A NITRATION WITH PHENYL INORGANIC ACID ESTER IN HYDROFLUORIC ACID AND THEN HYDROLYSIS RHONE-POULENC CHIMIE (FR) 1988-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115566-A1 Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof CALD1, CALU, CLASP1 LTA4H 4629/4885TSHR 370/4885CA4 2083/4885
US-20020026047-A1 Calixpyrroles, calixpyridinopyrroles, and calixpyridines CALD1, DAP3, CALR LTA4H 4295/4885TSHR 1925/4885CA4 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.